Andere talen MiNK Therapeutics, Inc.

Aandelen

INKT

US6036931029

Vertraagde tijd Nasdaq Andere beurzen 17:07:05 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,9716 ^USD	+2,26%		+11,55%	-9,20%

21/03	Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024
21/03	MiNK Therapeutics, Inc. Rapporteert winstresultaten voor het vierde kwartaal en het volledige jaar eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report	13:30
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR	08/04
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR	08/04
MiNK Reports Fourth Quarter and Year-End 2023 Results	21/03
MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	07/03
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report	07/03
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	06/03
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	06/03
MiNK Therapeutics, Inc. Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	06/03
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab	14/02
MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer	14/02
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.	12/02
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	06/02
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	06/02
Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	06/02
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	30/01
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	30/01
MiNK?s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	30/01
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development	20/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen MiNK Therapeutics, Inc.

Aandelen

INKT

US6036931029

Andere talen

Filters